Latest news and press releases about NewAmsterdam Pharma Company N.V. (NAMS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Price
| Price | $21.18 |
| Market Cap | $2.5B |
| Exchange | NASDAQ |
| Country | NL |
Valuation Ratios
| Price / Book | 5.45 |
| EV / EBITDA | -14.54 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -29.82% |
| Return on Invested Capital | -33.01% |
| Return on Assets | -26.49% |
| Gross Margin | 99.74% |
| Operating Margin | -1002.90% |
| Net Margin | -905.74% |
Related companies: ACLX · AKRO · CGON · CRNX · IMVT · KYMR · LGND
Explore sector: Healthcare · Biotechnology
More sections of NAMS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks